Keyphrases
Uveitis
100%
Steroid Treatment
51%
Toxoplasmosis
49%
Treatment Trials
48%
Building Program
38%
Congenital Toxoplasmosis
35%
Immunosuppression
26%
Panuveitis
26%
Ocular Toxoplasmosis
25%
Ocular Lesions
22%
Toxoplasma Gondii (T. gondii)
21%
Visual Acuity
19%
Cancer Incidence
19%
Subsequent Cancer
19%
AIDS/HIV
19%
Cytomegalovirus Retinitis
19%
First Year of Life
19%
Ocular Diseases
19%
Standardization of Uveitis Nomenclature
19%
Treatment Outcome
19%
Risk Factors
17%
Panama
17%
Colombia
17%
New Lesion
15%
Sulfadiazine
15%
Chorioretinitis
15%
Iris
14%
Best-corrected Visual Acuity
14%
Inflammation
14%
Confidence Interval
14%
Macula
13%
Fluocinolone Acetonide Implant
13%
Chorioretinal Lesions
13%
Systemic Corticosteroids
12%
Cataract
12%
Macular Edema
11%
Optical Coherence Tomography
11%
Epidemiology
11%
Adalimumab
11%
Visual Acuity Outcome
11%
Uveitic
11%
Fundus Image
11%
Chicago
10%
Interobserver Agreement
10%
Clinical Data
10%
Tumor
10%
Veterans Health Administration
10%
Educational Materials
9%
Vision Center
9%
Human Immunodeficiency Virus Infection
9%
Medicine and Dentistry
Uveitis
90%
Toxoplasmosis
41%
Steroid Treatment
41%
Congenital Toxoplasmosis
34%
Immunosuppressive Treatment
27%
Cohort Analysis
25%
Vitreous
24%
Infection
24%
Sarcoidosis
23%
Eye Injury
22%
Neoplasm
20%
Visual Acuity
19%
Cancer Incidence
19%
Cytomegalovirus Retinitis
19%
Diagnosis
15%
Iris
15%
Chorioretinitis
15%
Anterior Chamber of Eyeball
13%
Biopsy Technique
13%
Fluocinolone Acetonide
13%
Human Immunodeficiency Virus
13%
Acquired Immune Deficiency Syndrome
12%
Corticosteroid
12%
Recurrent Disease
12%
Sulfadiazine
12%
Cataract
12%
Implant
12%
Optical Coherence Tomography
12%
Best Corrected Visual Acuity
12%
Cytotechnology
11%
Public Health
11%
Adalimumab
11%
Macular Edema
11%
Disease
10%
Veterans Health
10%
Agents Acting on the Eye
10%
Immune Reconstitution
9%
Iridectomy
9%
Oncology
9%
Intraocular Foreign Body
9%
Mitochondrial DNA
9%
Ciliary Body
9%
Cohort Effect
9%
Toxoplasmic Chorioretinitis
9%
Point Mutation
9%
Seroprevalence
9%
Immune Reconstitution Inflammatory Syndrome
9%
Blau Syndrome
9%
Ranibizumab
9%
Neurologic Disease
9%